Mårten Fernö
101 – 150 of 255
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer.
(
- Contribution to journal › Article
-
Mark
P4-09-02: G Protein-Coupled Estrogen Receptor 1 Positively Correlates with Estrogen Receptor a Expression and Increased Distant Disease-Free Survival of Breast Cancer Patients.
(
- Contribution to journal › Published meeting abstract
- 2010
-
Mark
Three different antibodies for estrogen receptor analysis in breast cancer - implications for positive frequency, reproducibility and clinical outcome
(
- Contribution to journal › Published meeting abstract
-
Mark
Cyclin A - an alternative to gene expression profiling for subdividing histological grade 2 breast cancer into groups with different prognosis
(
- Contribution to journal › Published meeting abstract
-
Mark
Ki-67 as a long-term prognostic factor in lobular breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome.
(
- Contribution to journal › Article
-
Mark
Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?
(
- Contribution to journal › Article
-
Mark
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Article
-
Mark
Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1.
(
- Contribution to journal › Article
-
Mark
Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
(
- Contribution to journal › Article
-
Mark
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
(
- Contribution to journal › Article
-
Mark
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
2010) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23. p.251-259(
- Contribution to journal › Article
-
Mark
Modeling Prognostic Markers in Breast Cancer — Are We Using Them the Optimal Way?
(
- Contribution to journal › Published meeting abstract
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Expression of Helix pomatia Lectin Binding Glycoproteins in Women with Breast Cancer in Relationship to Their Mood Group Phenotypes
(
- Contribution to journal › Article
-
Mark
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Published meeting abstract
-
Mark
Cyclin B1 Is an Independent Prognostic Proliferation Marker with a High Reproducibility in a Population-Based Lymph Node Negative Breast Cancer Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Is the prognostic value of Ki-67 dependent on ER status and histological grade?
(
- Contribution to journal › Published meeting abstract
-
Mark
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
(
- Contribution to journal › Article
-
Mark
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574(
- Contribution to journal › Article
-
Mark
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - A national survey performed at pathology departments in Sweden.
(
- Contribution to journal › Article
- 2008
-
Mark
Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
(
- Contribution to journal › Article
-
Mark
Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome
(
- Contribution to journal › Article
-
Mark
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer
(
- Contribution to journal › Article
-
Mark
The CD44(+)/CD24(-) phenotype is enriched in basal-like breast tumors
(
- Contribution to journal › Article
-
Mark
Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail?
(
- Contribution to journal › Article
-
Mark
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
(
- Contribution to journal › Article
-
Mark
Epidermal Growth Factor Receptor (EGFR) in primary breast cancer-protein expression, but not gene copy number, gives important prognostic information in tamoxifen treated patients
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.187-187(
- Contribution to journal › Published meeting abstract
-
Mark
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
(
- Contribution to journal › Article
-
Mark
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
(
- Contribution to journal › Article
-
Mark
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
(
- Contribution to journal › Article
-
Mark
Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs.
(
- Contribution to journal › Article
-
Mark
Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor.
(
- Contribution to journal › Article
-
Mark
High amplified in breast cancer 1 is a significant predictor of improved response to adjuvant tamoxifen in premenopausal women
2008) 31st Annual San Antonio Breast Cancer Symposium(
- Contribution to conference › Abstract
- 2007
-
Mark
In-Source Decay Causes Artifacts in SELDI-TOF MS Spectra.
(
- Contribution to journal › Article
-
Mark
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
(
- Contribution to journal › Article
-
Mark
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
(
- Contribution to journal › Article
-
Mark
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
(
- Contribution to journal › Article
-
Mark
RNA quality in frozen breast cancer samples and the influence on gene expression analysis - a comparison of three evaluation methods using microcapillary electrophoresis traces
(
- Contribution to journal › Article
-
Mark
Serum protein profiling of metastatic breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Antibody microarray based oncoproteomics - analysis of breast cancer proteomes
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.
(
- Contribution to journal › Article
-
Mark
Antibody microarray based oncoproteomics - analysis of breast cancer proteomes
2006) 29th annual San Antonio breast cancer symposium In Proceedings of the 29th annual San Antonio breast cancer symposium(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
(
- Contribution to journal › Article
-
Mark
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
(
- Contribution to journal › Article